Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of aflibercept 8 mg every 16 weeks versus aflibercept 2 mg every 8 weeks in Chinese participants with diabetic macular edema
ChiCTR2500102811Phase 3Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Beijing Tongren Hospital. Started May 2025; status: recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2500102811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102811.